摘要
目的研究硫普罗宁片在健康人体内的相对生物利用度。方法采用高效液相色谱-质谱法(HPLC-MS)测定了18名健康男性受试者交叉po 200mg的硫普罗宁参比制剂和受试制剂后不同时间血浆中硫普罗宁的浓度,求出主要药动学参数,并进行方差分析和双单侧t检验。结果HPLC-MS测定血浆中硫普罗宁的线性范围为0.02～5mg·L-1,定量下限为0.02mg·L-1。日内、日间精密度(RSD)均小于13%,相对回收率介于96%～106%之间。硫普罗宁片参比制剂和受试制剂主要药动学参数:ρmax分别为(3.54±0.75)和(3.27±1.03)mg·L-1;tmax分别为(4.6±1.1)和(4.3±1.0)h;AUC0-96h分别为(18.2±4.5)和(17.6±5.9)mg·h·L-1;AUC0-∞分别为(20.4±5.5)和(19.9±6.9)mg·h·L-1;t1/2分别为(39.4±14.3)和(41.8±16.5)h。tmax经非参数秩和检验,受试制剂与参比制剂无统计学显著性差异;ρmax、AUC0-96h、AUC0-∞经对数转换后进行方差分析,受试制剂与参比制剂无统计学显著性差异,双向单侧t检验结果表明,受试制剂ρmax的90%可信限落在参比制剂70%～143%之间,受试制剂AUC的90%可信限落在参比制剂80%～125%之间;以AUC0-96h计算,受试制剂硫普罗宁片的相对生物利用度为(95.7±26.1)%。结论两种硫普罗宁片制剂具有生物等效性。
Abstract
OBJECTIVE To study the pharmacokinetics and bioequivalence of tiopronin tablets in healthy volunteers.METHODS In a randomized crossover study,18 healthy male volunteers were given a single oral dose of 200 mg test and reference tablets.Tiopronin in plasma was determined by a LC-MS method.RESULTS The main pharmacokinetic parameters for tiopronin of reference and test preparations in plasma were as follows:ρmax were(3.54±0.75) and(3.27±1.03) mg·L-1;tmax were(4.6±1.1) and(4.3±1.0) h;AUC0-96 h were(18.2±4.5) and(17.6±5.9) mg·h·L-1;AUC0-∞ were(20.4±5.5) and(19.9 ± 6.9) mg·h·L-1;t1/2 were(39.4±14.3) and(41.8±16.5) h,respectively.The relative bioavailability of tiopronin was(95.7±26.1)%.CONCLUSION The test and reference preparations were bioequivalent.
关键词
硫普罗宁 /
高效液相色谱-质谱 /
药动学 /
生物等效性
{{custom_keyword}} /
Key words
tiopronin /
liquid chromatography-mass spectrometry /
pharmacokinetics
{{custom_keyword}} /
吴红海;刘建芳;张运好;侯艳宁.
血浆中硫普罗宁的测定及其片剂人体生物等效性研究[J]. 中国药学杂志, 2008, 43(11): 855-857
WU Hong-hi;LIU Jin-fng;ZHNG Yun-ho;HOU Yn-ning.
Determination of Tiopronin in Human Plasma and Study on Its Bioequivalence [J]. Chinese Pharmaceutical Journal, 2008, 43(11): 855-857
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] WEI D，LAN Q Q. New drug tiopronin[J] .Chin J Biochem Pharm(中国生化药物杂志)，1997，18(6)： 322-323.
[2] CARLSSON M S，SENNEBERG T，EMANUELSSON B M，et al. Pharmacokinetics of oral tiopronin[J] .Eur J Clin Pharmacol，1993，45（1）：79-84.
[3] HERCELIN B，LEROY P，NICOLAS A，et al.The pharmacyokinetics of tiopronin and its principal metabolite (2-mercaptopropionic acid) after oral administration to healthy volunteers[J] .Eur J Clin Parmacol，1992，43（1）：93-95.
[4] XIONG Z H，GUO Q Y，WU H Y，et al.Relative bioavailability of tiopronine tablets in healthy volunteers[J] .Chin J Clin Pharmacol(中国临床药理学杂志)，1997，13(3)：153-156.
[5] MATSUURA K，MURAI K，FUKANO Y，et al.Simutneous determintion of tiopronin and its metabolites in rat blood by LC-ESI-MS-MS using methyl acrylate for stabilization of thiol group[J] .J Pharm Biomed Anal，2000，22(1)：101-109.
[6] MA J，GU Y，CHEN B，et al.High-performance liquid chromatography-electronspray ionization mass spectrometry for determination of tiopronin in human plasma[J] .J Chromatogr A，2006，1113 (1-2)： 55-59.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
